Rezultati - Scott Gettinger

Refine Results
  1. 1
    PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

    PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? od Scott Gettinger, Katerina Politi

    Izdano 2016
    Polni tekst
    Carta
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Oncolytic virus immunotherapy: future prospects for oncology

    Oncolytic virus immunotherapy: future prospects for oncology od Junaid Raja, Johannes Ludwig, Scott Gettinger, Kurt A. Schalper, Hyun S. Kim

    Izdano 2018
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer

    SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer od Kavita M. Dhodapkar, Scott Gettinger, Rituparna Das, Henry Zebroski, Madhav V. Dhodapkar

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial

    An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial od Ruth McCorkle, Sangchoon Jeon, Elizabeth Ercolano, Mark Lazenby, Amanda Reid, Marianne Davies, Diane Viveiros, Scott Gettinger

    Izdano 2015
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy

    Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy od Jing W. Hughes, Nalini Vudattu, Mario Sznol, Scott Gettinger, Harriet M. Kluger, Beatrice Lupsa, Kevan C. Herold

    Izdano 2015
    Polni tekst Polni tekst
    Carta
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

    Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy od Veronica Shi, Nemanja Rodić, Scott Gettinger, Jonathan S. Leventhal, Julia P. Neckman, Michael Girardi, Marcus Bosenberg, Jennifer Choi

    Izdano 2016
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)

    Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC) od Daniel E. Carvajal-Hausdorf, Mehmet Altan, Vamsidhar Velcheti, Scott Gettinger, Roy S. Herbst, David L. Rimm, Kurt A. Schalper

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer

    Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer od Johannes Uhlig, Meaghan Dendy Case, Justin D. Blasberg, Daniel J. Boffa, Anne C. Chiang, Scott Gettinger, Hyun S. Kim

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling

    Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling od Jon Zugazagoitia, Swati Gupta, Yuting Liu, Kit Fuhrman, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm

    Izdano 2020
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer

    Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer od Gregory A. Otterson, Miguel A. Villalona‐Calero, William J. Hicks, Xueliang Pan, John Ellerton, Scott Gettinger, John R. Murren

    Izdano 2010
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

    Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy od Kathleen C. Suozzi, Maximilian Stahl, Christine J. Ko, Anne C. Chiang, Scott Gettinger, Mark D. Siegel, Christopher G. Bunick

    Izdano 2016
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

    Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy od Yuting Liu, Jon Zugazagoitia, Fahad Shabbir Ahmed, Brian S. Henick, Scott Gettinger, Roy S. Herbst, Kurt A. Schalper, David L. Rimm

    Izdano 2019
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    Treatment of Stage IV Non-small Cell Lung Cancer

    Treatment of Stage IV Non-small Cell Lung Cancer od Mark A. Socinski, Tracey L. Evans, Scott Gettinger, Thomas A. Hensing, Lecia VanDam Sequist, Belinda Ireland, Thomas E. Stinchcombe

    Izdano 2013
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Immune Checkpoint Inhibitor–Associated Pericarditis

    Immune Checkpoint Inhibitor–Associated Pericarditis od Mehmet Altan, Maria Toki, Scott Gettinger, Daniel E. Carvajal-Hausdorf, Jon Zugazagoitia, John H. Sinard, Roy S. Herbst, David L. Rimm

    Izdano 2019
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    Identification of <i>EGFR</i> mutation, <i>KRAS</i> mutation, and <i>ALK</i> gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma

    Identification of <i>EGFR</i> mutation, <i>KRAS</i> mutation, and <i>ALK</i> gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma od Guoping Cai, Rebecca A. Wong, David C. Chhieng, Gillian H. Levy, Scott Gettinger, Roy S. Herbst, Jonathan Puchalski, Robert Homer, Pei Hui

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas

    High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas od Vamsidhar Velcheti, Kurt A. Schalper, Xiaopan Yao, Huan Cheng, Mehmet H. Kocoglu, Kavita M. Dhodapkar, Yanhong Deng, Scott Gettinger, David L. Rimm

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Programmed death ligand-1 expression in non-small cell lung cancer

    Programmed death ligand-1 expression in non-small cell lung cancer od Vamsidhar Velcheti, Kurt A. Schalper, Daniel Carvajal, Valsamo Anagnostou, Konstantinos N. Syrigos, Mario Sznol, Roy S. Herbst, Scott Gettinger, Lieping Chen, David L. Rimm

    Izdano 2013
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing

    Ultrasensitive Measurement of Hotspot Mutations in Tumor DNA in Blood Using Error-Suppressed Multiplexed Deep Sequencing od Azeet Narayan, Nicholas Carriero, Scott Gettinger, Jeannie Kluytenaar, Kevin R. Kozak, Torunn I. Yock, Nicole E. Muscato, Pedro Ugarelli, Roy H. Decker, Abhijit A. Patel

    Izdano 2012
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer

    A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer od Kimberly L. Johung, Xiaopan Yao, Fangyong Li, James B. Yu, Scott Gettinger, Sarah B. Goldberg, Roy H. Decker, Judith Hess, Veronica Chiang, Joseph N. Contessa

    Izdano 2013
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors

    Activity of Afatinib/Cetuximab in Patients (PTS) with EGFR Mutant Non-Small Cell Lung Cancer (Nsclc) and Acquired Resistance (Ar) To EGFR Inhibitors od Y. Y. Janjigian, Egbert F. Smit, Leora Horn, Harry J.M. Groen, D. Ross Camidge, Scott Gettinger, Yali Fu, L. Denis, V.A. Miller, William Pao

    Izdano 2012
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: